MedTrace Logo

EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

NCT00647192 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2012-02-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether Eplerenone reduces atrial fibrillation (AF) recurrences within the first 8 weeks after electrical cardioversion of persistent AF.

Conditions

Interventions

DRUG

Eplerenone

50 mg per day

DRUG

Placebo

50 mg per day

Sponsors & Collaborators

  • University Medical Center Groningen

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • University Hospital, Saarland

    lead OTHER

Principal Investigators

  • Michael Böhm, MD · Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00647192 on ClinicalTrials.gov